Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid

Bibliography

• Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003;362:53-61
   PubMed Web of Science ®Google Scholar
• Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007;357:1524-9
   PubMed Web of Science ®Google Scholar
• Kim WR, Lindor KD, Locke GR III, Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631-6
   PubMed Web of Science ®Google Scholar
• Cavazza A, Caballeria L, Floreani A, Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009;50:1162-8
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, Primary biliary cirrhosis. Hepatology 2009;50:291-308
   PubMed Web of Science ®Google Scholar
• Nijhawan PK, Therneau TM, Dickson ER, Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 1999;29:1396-8
   Google Scholar
• Springer JE, Cole DE, Rubin LA, Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145-51
   PubMed Web of Science ®Google Scholar
• Menon KV, Angulo P, Weston S, Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316-23
   PubMed Web of Science ®Google Scholar
• Guanabens N, Pares A, Ros I, Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2268-74
   PubMedGoogle Scholar
• Floreani A, Carderi I, Ferrara F, A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig Liver Dis 2007;39:544-8
   Google Scholar
• Zein CO, Jorgensen RA, Clarke B, Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762-71
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Tiegs RD, Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000;33:878-82
   Google Scholar
• Longo M, Crosignani A, Battezzati PM, Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51:265-269
   PubMed Web of Science ®Google Scholar
• Crippin JS, Lindor KD, Jorgensen R, Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992;15:858-62
   PubMed Web of Science ®Google Scholar
• Allocca M, Crosignani A, Gritti A, Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006;55:1795-1800
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Elta GH, Furie B, Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988;95:787-92
   PubMed Web of Science ®Google Scholar
• Phillips JR, Angulo P, Petterson T, Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001;96:2745-50
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Davis GL, Schafer DF, Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986;91:1327-34
   PubMed Web of Science ®Google Scholar
• Dickson ER, Fleming TR, Wiesner RH, Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985;312:1011-5
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Ludwig J, Lindor KD, A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990;322:1419-24
   PubMed Web of Science ®Google Scholar
• Lombard M, Portmann B, Neuberger J, Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993;104:519-26
   PubMed Web of Science ®Google Scholar
• Mitchison HC, Palmer JM, Bassendine MF, A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992;15:336-44
   PubMed Web of Science ®Google Scholar
• Christensen E, Neuberger J, Crowe J, Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89:1084-91
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Angulo P, Keach JC, Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005;39:168-71
   PubMed Web of Science ®Google Scholar
• Hendrickse MT, Rigney E, Giaffer MH, Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999;117:400-7
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Alling DW, Zimmerman HJ, A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986;315:1448-54
   PubMed Web of Science ®Google Scholar
• Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. a Cochrane hepato-biliary group systematic review of randomized clinical trials. Am J Gastroenterol 2005;100(8):1876-85
   Google Scholar
• Angulo P, Dickson ER, Therneau TM, Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-5
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VA, High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Stieger B, Hagenbuch B, Hepatic transport of bile salts. Semin Liver Dis 2000;20:273-92
   PubMed Web of Science ®Google Scholar
• Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 1994;204:1-15
   PubMedGoogle Scholar
• Saksena S, Tandon RK. Ursodeoxycholic acid in the treatment of liver diseases. Postgrad Med J 1997;73:75-80
   PubMed Web of Science ®Google Scholar
• Setchell KD, Rodrigues CM, Podda M, Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 1996;38:439-446
   Google Scholar
• Ward A, Brogden RN, Heel RC, Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 1984;27:95-131
   PubMed Web of Science ®Google Scholar
• Stiehl A, Benz C, Sauer P. Mechanism of hepatoprotective action of bile salts in liver disease. Gastroenterol Clin North Am 1999;28:195-209, viii
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001;35:134-46
   PubMed Web of Science ®Google Scholar
• Cohen J, Somma-Delpero C, Verine A, Increased monoester lipase activity in red blood cells during hyperthyroidism. J Endocrinol 1986;108:357-9
   Google Scholar
• Jorgensen RA, Dickson ER, Hofmann AF, Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995;36:935-938
   PubMedGoogle Scholar
• Balan V, Dickson ER, Jorgensen RA, Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc 1994;69:923-9
   PubMed Web of Science ®Google Scholar
• Angulo P, Batts KP, Therneau TM, Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-7
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J, Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000;32:561-6
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Bonnand AM, The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Therneau TM, Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137-40
   PubMed Web of Science ®Google Scholar
• Prince M, Chetwynd A, Newman W, Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-51
   PubMed Web of Science ®Google Scholar
• Springer J, Cauch-Dudek K, O'Rourke K, Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999;94:47-53
   PubMed Web of Science ®Google Scholar
• Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:707-13
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Bahr A, The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303
   PubMed Web of Science ®Google Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-60
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007;102:1799-807
   PubMed Web of Science ®Google Scholar
• Mendes FD, Kim WR, Pedersen R, Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008;47:1241-7
   Google Scholar
• Angulo P, Lindor KD, Therneau TM, Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999;19:115-21
   PubMedGoogle Scholar
• Lindor KD, Janes CH, Crippin JS, Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995;21:389-92
   PubMed Web of Science ®Google Scholar
• Siegel JL, Jorgensen R, Angulo P, Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003;37:183-5
   PubMed Web of Science ®Google Scholar
• Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008;48:1149-56
   PubMed Web of Science ®Google Scholar